107 related articles for article (PubMed ID: 35786485)
1. [Identifying SARS-CoV-2 main protease inhibitors by a novel sandwich-like fluorescence polarization screening assay].
Yan H; Yan G; Qi H; Liu Z; Liu X; Liu X; Li N; Chen Y
Sheng Wu Gong Cheng Xue Bao; 2022 Jun; 38(6):2352-2364. PubMed ID: 35786485
[TBL] [Abstract][Full Text] [Related]
2. Development of a simple and miniaturized sandwich-like fluorescence polarization assay for rapid screening of SARS-CoV-2 main protease inhibitors.
Yan G; Li D; Lin Y; Fu Z; Qi H; Liu X; Zhang J; Si S; Chen Y
Cell Biosci; 2021 Dec; 11(1):199. PubMed ID: 34865653
[TBL] [Abstract][Full Text] [Related]
3. A robust high-throughput fluorescence polarization assay for rapid screening of SARS-CoV-2 papain-like protease inhibitors.
Yan H; Liu Z; Yan G; Liu X; Liu X; Wang Y; Chen Y
Virology; 2022 Sep; 574():18-24. PubMed ID: 35870326
[TBL] [Abstract][Full Text] [Related]
4. [Discovery of SARS-CoV-2 main protease inhibitors using an optimized FRET-based high-throughput screening assay].
Yan G; Li D; Qi H; Fu Z; Liu X; Zhang J; Chen Y
Sheng Wu Gong Cheng Xue Bao; 2022 Jun; 38(6):2236-2249. PubMed ID: 35786475
[TBL] [Abstract][Full Text] [Related]
5. Improved fluorescence-based assay for rapid screening and evaluation of SARS-CoV-2 main protease inhibitors.
Zhang R; Yan H; Zhou J; Yan G; Liu X; Shang C; Chen Y
J Med Virol; 2024 Mar; 96(3):e29498. PubMed ID: 38436148
[TBL] [Abstract][Full Text] [Related]
6. Biochemical screening for SARS-CoV-2 main protease inhibitors.
Coelho C; Gallo G; Campos CB; Hardy L; Würtele M
PLoS One; 2020; 15(10):e0240079. PubMed ID: 33022015
[TBL] [Abstract][Full Text] [Related]
7. Invalidation of geraniin as a potential inhibitor against SARS-CoV-2 main protease.
Zhang R; Yan H; Zhou J; Liu X; Chen Y
Nat Prod Res; 2024 Jun; 38(12):2078-2081. PubMed ID: 37533400
[TBL] [Abstract][Full Text] [Related]
8. Protocol for high-throughput screening of SARS-CoV-2 main protease inhibitors using a robust fluorescence polarization assay.
Zhang J; Yan H; Yan G; Liu X; Wang Y; Chen Y
STAR Protoc; 2022 Dec; 3(4):101794. PubMed ID: 36317181
[TBL] [Abstract][Full Text] [Related]
9. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
[TBL] [Abstract][Full Text] [Related]
10. In silico discovery of novel inhibitors from Northern African natural products database against main protease (Mpro) of SARS-CoV-2.
Byadi S; Oblak D; Kassmi Y; Sadik K; Hachim ME; Podlipnik Č; Aboulmouhajir A
J Biomol Struct Dyn; 2023 Apr; 41(7):2900-2910. PubMed ID: 35168469
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 main protease cleaves MAGED2 to antagonize host antiviral defense.
Ju X; Wang Z; Wang P; Ren W; Yu Y; Yu Y; Yuan B; Song J; Zhang X; Zhang Y; Xu C; Tian B; Shi Y; Zhang R; Ding Q
mBio; 2023 Aug; 14(4):e0137323. PubMed ID: 37439567
[TBL] [Abstract][Full Text] [Related]
12. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
13. Ginkgolic acid and anacardic acid are reversible inhibitors of SARS-CoV-2 3-chymotrypsin-like protease.
Li D; Yan G; Zhou W; Si S; Liu X; Zhang J; Li Y; Chen Y
Cell Biosci; 2022 May; 12(1):65. PubMed ID: 35590420
[TBL] [Abstract][Full Text] [Related]
14. A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition.
Dey-Rao R; Smith GR; Timilsina U; Falls Z; Samudrala R; Stavrou S; Melendy T
Antiviral Res; 2021 Nov; 195():105183. PubMed ID: 34626674
[TBL] [Abstract][Full Text] [Related]
15. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors.
Jiménez-Alberto A; Ribas-Aparicio RM; Aparicio-Ozores G; Castelán-Vega JA
Comput Biol Chem; 2020 Oct; 88():107325. PubMed ID: 32623357
[TBL] [Abstract][Full Text] [Related]
16. [Optimization of expression conditions and determination the proteolytic activity of codon-optimized SARS-CoV-2 main protease in Escherichia coli].
Chen Y; Fu Z; Yan G; Lin Y; Liu X
Sheng Wu Gong Cheng Xue Bao; 2021 Apr; 37(4):1334-1345. PubMed ID: 33973446
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2.
Zhao Y; Zhu Y; Liu X; Jin Z; Duan Y; Zhang Q; Wu C; Feng L; Du X; Zhao J; Shao M; Zhang B; Yang X; Wu L; Ji X; Guddat LW; Yang K; Rao Z; Yang H
Proc Natl Acad Sci U S A; 2022 Apr; 119(16):e2117142119. PubMed ID: 35380892
[TBL] [Abstract][Full Text] [Related]
18. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
Amin SA; Banerjee S; Ghosh K; Gayen S; Jha T
Bioorg Med Chem; 2021 Jan; 29():115860. PubMed ID: 33191083
[TBL] [Abstract][Full Text] [Related]
19. Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor.
Tan H; Ma C; Wang J
Med Chem Res; 2022; 31(7):1147-1153. PubMed ID: 35578732
[TBL] [Abstract][Full Text] [Related]
20. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.
Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S
Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
